{"id":"placebo-to-match-amlodipine","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo-to-match products are inactive formulations engineered to be indistinguishable from the active drug in terms of appearance, taste, texture, and packaging. They are used in randomized controlled trials to maintain blinding and reduce bias. This specific placebo is formulated to match amlodipine, a calcium channel blocker, but contains no active pharmaceutical ingredient.","oneSentence":"This is an inert placebo formulation designed to match the appearance and administration of amlodipine for use in blinded clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:27.473Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Use as control in clinical trials comparing amlodipine efficacy and safety"}]},"trialDetails":[{"nctId":"NCT06236061","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Hypertension","enrollment":718},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT01277822","phase":"PHASE4","title":"Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-05-30","conditions":"Hypertension","enrollment":334},{"nctId":"NCT02979197","phase":"PHASE3","title":"Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives","status":"COMPLETED","sponsor":"Kitov Pharma Ltd","startDate":"2016-11-03","conditions":"Hypertension","enrollment":105},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT02172040","phase":"PHASE3","title":"Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy","status":"COMPLETED","sponsor":"Kitov Pharmaceuticals, Ltd.","startDate":"2014-06-26","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01264692","phase":"PHASE2","title":"Essential Hypertension","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2011-02","conditions":"Essential Hypertension","enrollment":196},{"nctId":"NCT02969265","phase":"PHASE3","title":"An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2017-05-09","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01975246","phase":"PHASE3","title":"Add-on to Micamlo BP Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Hypertension","enrollment":309},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT01911780","phase":"PHASE3","title":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07","conditions":"Hypertension","enrollment":132},{"nctId":"NCT01663233","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Essential Hypertension","enrollment":266},{"nctId":"NCT01130168","phase":"PHASE1","title":"The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05","conditions":"Hypertension","enrollment":38},{"nctId":"NCT01631864","phase":"PHASE2","title":"Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Hypertension, Concurrent Obesity","enrollment":98},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00437645","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Essential Hypertension","enrollment":1183},{"nctId":"NCT00498433","phase":"PHASE2","title":"Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-06","conditions":"Hypertension, Abdominal Obesity","enrollment":46},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Hypertension, Stage 2 Hypertension, Diabetes","enrollment":975},{"nctId":"NCT01237223","phase":"PHASE3","title":"Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Essential Hypertension","enrollment":1342},{"nctId":"NCT00591266","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Hypertension","enrollment":566},{"nctId":"NCT00699192","phase":"PHASE3","title":"Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-05","conditions":"Hypertension","enrollment":965},{"nctId":"NCT00413049","phase":"PHASE3","title":"Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Hypertension","enrollment":698},{"nctId":"NCT00413413","phase":"PHASE3","title":"Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Hypertension","enrollment":1134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to match amlodipine","genericName":"Placebo to match amlodipine","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the appearance and administration of amlodipine for use in blinded clinical trials. Used for Use as control in clinical trials comparing amlodipine efficacy and safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}